Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Observational

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

NCT05987189 · tracked via the Priya Life Science USA tracker
Sponsor
Hummingbird Diagnostics
Phase
Observational
Started
2023-10-18
Last updated
2026-09-30

Condition(s) studied

Lung Cancer

Investigational drug(s) / intervention(s)

Small RNA-based lung cancer assay

Small RNA-based lung cancer assay: At study enrollment, a blood sample is collected prior to any invasive diagnostic procedure or treatment. A small RNA-based lung cancer assay is performed on the collected blood sample for research purposes. Assay results are not returned to participants or investigators and are not used for clinical decision-making.

Study summary

2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at one of the participating hospitals.

Eligibility

Sex
ALL
Min age
50 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Adult male and female patients, aged 50 to 80 years * Received a lung RADS category 3 or 4 finding on a LDCT screening exam (first or subsequent) and are referred to undergo further diagnostic procedures for the detection of lung cancer * Has undergone LD-CT screening exam within last 90 days and allows for blood sampling within this period * Subject may not have undergone any invasive diagnostic procedure in relation to the suspicious nodule * Able and willing to provide informed consent Exclusion Criteria: * Prior history of diagnosed lung cancer * History of gastrointestinal, hematological, breast, thyroid, and genitourinary cancer within the past 10 years * Active infectious diseases, such blood borne viral diseases (e.g. AIDS, hepatitis) * Immunosuppressive medication * Deemed not able to participate in the study by the investigator

Primary outcome measure(s)

  • Primary Objective — 1 year
    The study is a prospective, longitudinal, observational study to evaluate the performance of a novel diagnostic test for early-stage lung cancer. The primary endpoint is to detect the presence or absence of lung cancer, as determined by all follow-up imaging, and pathological data obtained throughout the duration of the study.

Trial sites (11)

FacilityCityRegionStatus
Northside Hospital Atlanta Georgia
Our Lady of the Lake Regional Medical Center Baton Rouge Louisiana
Brigham and Women's Hospital Boston Massachusetts
Mass General Hospital Boston Massachusetts
UMass Chan Medical School/UMass Memorial Health Worcester Massachusetts
Henry Ford Health Detroit Michigan
New York Health + Elmhurst Hospitals Queens New York
Jacobi Medical Center The Bronx New York
Clinical Research Associates of Central PA DuBois Pennsylvania
Baptist Hospitals of Southeast Texas Beaumont Texas
University Of Utah Health Salt Lake City Utah
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05987189 on ClinicalTrials.gov ↗ ← All trials in the USA